In this episode of the SynBioBeta Human Health podcast Fiona Mischel interviews bit.bio CEO Mark Kotter.
They discuss how, with groundbreaking technologies like human cell reprogramming, we're now venturing beyond the "Brother Wright Flight" of early CAR-T therapies and making these novel cell therapies more accessible to all patients. The conversation covers the vision for achieving this goal, upcoming challenges, and the various opportunities that synthetic biology offers.
Access the episode here.
